XML 23 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
 9 Months Ended
Sep. 30, 2013
Segment Reporting [Abstract]  
Operating Segment And Geographic Information
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
Our chief operating decision-maker is our Chief Executive Officer, who regularly evaluates our performance based on net sales and net loss before taxes. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be directionally correct, actual results could differ from the estimates and assumptions used in preparing this information.
The accounting policies of the segments are the same as the policies discussed in Note 2 – “Summary of Significant Accounting Policies” to the notes to our accompanying unaudited condensed consolidated financial statements.
In the first quarter of 2013, we consolidated our Clinical Laboratories and Pharmacogenomic Services business segments into a single segment and, going forward, the combined segment will be referred to as our Laboratory Services segment. We now have two reportable operating segments, Laboratory Services and Diagnostic Tools. Accordingly, segment results for the three and nine months ended September 30, 2012 have been reclassified to reflect these changes.
 
Segment information for the three months ended September 30, 2013 and 2012 is as follows:
 
 
Dollars in Thousands
 
September 30, 2013
 
Laboratory Services
 
Diagnostic
Tools
 
Total
Net Sales
$
4,112

 
$
2,534

 
$
6,646

Gross Profit
1,776

 
1,075

 
2,851

Net Loss before Taxes
(4,375
)
 
(1,185
)
 
(5,560
)
Income Tax Benefit
—

 
(8
)
 
(8
)
Net Loss
$
(4,375
)
 
$
(1,177
)
 
$
(5,552
)
Depreciation/Amortization
$
606

 
$
65

 
$
671

Interest Expense, net
$
(96
)
 
$
(59
)
 
$
(155
)
 
 
 
 
 
 
 
September 30, 2013
Total Assets
$
23,648

 
$
9,532

 
$
33,180


 
 
 
 
 
 
 
Dollars in Thousands
 
September 30, 2012
 
Laboratory Services
 
Diagnostic
Tools
 
Total
Net Sales
$
4,718

 
$
3,171

 
$
7,889

Gross Profit
2,347

 
1,453

 
3,800

Net Income (Loss) before Taxes
(1,907
)
 
(733
)
 
(2,640
)
Income Tax Benefit
—

 
114

 
114

Net Income (Loss)
$
(1,907
)
 
$
(847
)
 
$
(2,754
)
Depreciation/Amortization
$
442

 
$
53

 
$
495

Interest Expense, net
$
(201
)
 
$
(6
)
 
$
(207
)
 
 
 
 
 
 
 
September 30, 2012
Total Assets
$
30,553

 
$
12,334

 
$
42,887


Segment information for the nine months ended September 30, 2013 and 2012 is as follows:
 
Dollars in Thousands
 
September 30, 2013
 
Laboratory Services
 
Diagnostic
Tools
 
Total
Net Sales
$
12,551

 
$
8,775

 
$
21,326

Gross Profit
5,822

 
4,120

 
9,942

Net Loss before Taxes
(9,641
)
 
(2,312
)
 
(11,953
)
Income Tax Expense
—

 
52

 
52

Net Loss
$
(9,641
)
 
$
(2,364
)
 
$
(12,005
)
Depreciation/Amortization
$
1,815

 
$
287

 
$
2,102

Interest Expense, net
$
(314
)
 
$
(145
)
 
$
(459
)


 
 
 
 
 
 
 
Dollars in Thousands
 
September 30, 2012
 
Laboratory Services
 
Diagnostic
Tools
 
Total
Net Sales
$
14,527

 
$
9,661

 
$
24,188

Gross Profit
7,111

 
4,355

 
11,466

Net Income (Loss) before Taxes
(4,619
)
 
(1,307
)
 
(5,926
)
Income Tax Benefit
—

 
88

 
88

Net Income (Loss)
$
(4,619
)
 
$
(1,395
)
 
$
(6,014
)
Depreciation/Amortization
$
1,357

 
$
213

 
$
1,570

Interest Expense, net
$
(676
)
 
$
(37
)
 
$
(713
)

Net sales for the three and nine months ended September 30, 2013 and 2012 by country were as follows:
 
 
Dollars in Thousands
 
Dollars in Thousands
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2013
 
2012
 
2013
 
2012
United States
$
5,095

 
$
5,442

 
$
16,241

 
$
17,013

Italy
398

 
571

 
1,225

 
2,277

All Other Countries
1,153

 
1,876

 
3,860

 
4,898

Total
$
6,646

 
$
7,889

 
$
21,326

 
$
24,188


Other than the countries specifically identified above, no other country individually accounted for more than 5% of total net sales.

Approximately 99% of our long-lived assets are located within the United States.